Funding for this research was provided by:
Beijing Hope Run Special Fund of Cancer Foundation of China (LC2016L04)
National Key Projects of Research and Development of China (2016YFC0904600)
Text and Data Mining valid from 2019-04-29
Received: 25 November 2018
Accepted: 28 March 2019
First Online: 29 April 2019
Change Date: 23 May 2019
Change Type: Correction
Change Details: Following publication of the original article , the authors reported that an error in the Methods/Design, Study design and objectives section (third sentence).
Ethics approval and consent to participate
: Institutional review board approval was obtained for the 3JECROG P-01 trial from the ethical committee of the Chinese Academy of Medical Sciences (reference number NCC2016 YL-06), of Anyang Cancer Hospital (AZLL 022017002170116), of Tianjin Cancer Hospital (E2018309), of Fujian Cancer Hospital (SQ2019–037-01). The 3JECROG P-01 trial is published under NCT02979691 on ExternalRef removed. Written informed consent is obtained from all participants.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.